Global market of dietary supplement is welcoming a rising star GLYMATE

Food and Healthcare Press Releases Monday August 19, 2019 08:00
BREA, California--19 Aug--PRNewswire/InfoQuest

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product, which is available to consumers worldwide.

Glymate(TM) is an intense cellular regeneration dietary supplement that benefits the human body at multiple levels, and its patented key ingredient differentiates itself from other products. Our cellular regeneration technology promotes healthy insulin sensitivity and production which helps to break down glucose from food and transfer to energy*. When Glymate(TM) is consumed consistently, it helps our body energized and promotes bodyweight loss*. It is currently available through the company website and Amazon; we are also working with distributors for greater market access worldwide.

Today, there are more than 400 millions of people in the world are suffering from diabetes and the number of people who have high sugar blood level to prediabetes condition is much greater. "It's urgent that we take swift action to effectively treat and prevent this serious disease," a statement from the CDC reads. Glymate has dedicated years of research and numerous trials specifically to help the urgent needs of humans to address and prevent the seriousness of this problem. Glymate(TM) uses only all-natural ingredients, it is dairy-free, soy-free, gluten-free, wheat-free, no sugar, no preservatives and it's manufactured by Robinson in California. Its uniquely formulated soft gel with its proprietary patented regeneration technology is designed to help improve and balance blood sugar, cholesterol, and triglyceride levels by promoting healthy lipid metabolism*. It is carefully blended to increase the solubility and absorbency of the active ingredients. Glymate(TM)'s key ingredient affects the body at the molecular level and has a variety of functions inside cells*.

About Glymate(TM) Corp.

The Glymate(TM) Corp. is a privately held company, a global leader in health and wellness backed by a proven track record in its patented key ingredient. As a marketer and online seller of dietary supplements, we are committed to supporting consumers' wellness needs through high-quality product backed by science.

To learn more about Glymate(TM), please visit https://www.glymateusa.com. Follow Glymate(TM) on Instagram now at @glymate_usa.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Logo - https://mma.prnewswire.com/media/959709/Glymate_Logo.jpg

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics